VRAX
Virax Biolabs Group Limited Ordinary Shares
NASDAQ: VRAX · HEALTHCARE · BIOTECHNOLOGY
$0.13
-0.81% today
Updated 2026-04-30
Market cap
$993260.00
P/E ratio
—
P/S ratio
332.64x
EPS (TTM)
$-1.22
Dividend yield
—
52W range
$0 – $1
Volume
15.9M
Virax Biolabs Group Limited Ordinary Shares (VRAX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $99876.00 | $123820.00 | $0.00 | $8561.00 | $156419.00 | $6331.00 |
| Revenue growth (YoY) | — | +24.0% | -100.0% | — | +1727.1% | -96.0% |
| Cost of revenue | $54127.00 | $133254.00 | $0.00 | $9926.00 | $105829.00 | $59398.00 |
| Gross profit | $45749.00 | $-9434.00 | $0.00 | $-1365.00 | $50590.00 | $-53067.00 |
| Gross margin | 45.8% | -7.6% | — | -15.9% | 32.3% | -838.2% |
| R&D | $87000.00 | $120221.00 | $433743.00 | $397109.00 | $1.56M | $1.78M |
| SG&A | $602303.00 | $457680.00 | $1.29M | $5.31M | $4.59M | $4.33M |
| Operating income | $-651244.00 | $-644540.00 | $-1.73M | $-5.73M | $-6.50M | $-6.16M |
| Operating margin | -652.1% | -520.5% | — | -66963.7% | -4153.3% | -97344.8% |
| EBITDA | $2470.00 | $-644540.00 | $-750.00 | $-5.44M | $-6.61M | $-5.80M |
| EBITDA margin | 2.5% | -520.5% | — | -63570.7% | -4225.3% | -91649.5% |
| EBIT | $-648774.00 | $-1.29M | $-1.73M | $-5.44M | $-6.71M | $-6.15M |
| Interest expense | $90690.00 | $28643.00 | $15438.00 | $15468.00 | $26878.00 | $58179.00 |
| Income tax | $61667.00 | $-666469.00 | $-1.77M | $-271.00 | $-194474.00 | $-136661.00 |
| Effective tax rate | -8.3% | 50.6% | 50.9% | 0.0% | 2.8% | 2.2% |
| Net income | $-801131.00 | $-650984.00 | $-1.71M | $-5.46M | $-6.73M | $-6.06M |
| Net income growth (YoY) | — | +18.7% | -162.5% | -219.4% | -23.4% | +10.0% |
| Profit margin | -802.1% | -525.8% | — | -63748.3% | -4304.8% | -95739.2% |